EUVIMEDEUVIMED entdecken
Crossref

PRIM2 promotes proliferation and metastasis of pancreatic ductal adenocarcinoma through interactions with FAM111B

Jingyang Yin, Fanbo Qin, Hui Chen, Xianxing Wang, Renpei Xia, Bing Ni, Huaizhi Wang

Medical Oncology · 2024

DOI: 10.1007/s12032-024-02554-8 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Medical Oncology, 2024. Verfasst von Jingyang Yin und 6 weiteren Autor:innen. Beteiligte Einrichtung: University of Chinese Academy of Sciences (UCAS) Chongqing School, Chongqing Medical University, Chongqing, P. R. China. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Cell Proliferation, Pancreatic Neoplasms, Epithelial-Mesenchymal Transition. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 29 Literaturangaben. Gefördert von: National Natural Science Foundation of China, Technology Innovation and Application Development Project of Chongqing, China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Pancreatic ductal adenocarcinomas (PDAC) are huge threat to human for the extreme malignancy. PRIM2 was reported as tumor marker, while the functions and regulatory mechanisms in PDAC are still unclear. The study aimed to investigate the function of PRIM2 in PDAC. METHODS: Expression was detected using immunohistochemistry (IHC), Western blot, and real-time quantitative PCR (RT-qPCR) methods. Cell assays and xenograft model confirmed the phenotypes. Co-Immunoprecipitation (Co-IP) and protein stability assays were used for protein interactions. RESULTS: Inhibiting PRIM2 resulted in decreased proliferation and migration both in vitro and in vivo. PRIM2 upregulated FAM111B at increased RNA levels and protein stability. CONCLUSION: PRIM2/FAM111B axis promoted proliferation and migration by modulating the PI3K/AKT and epithelial-mesenchymal transition (EMT) markers. The axis has the potential to be targeted for PDAC treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalCell ProliferationPancreatic NeoplasmsEpithelial-Mesenchymal TransitionHumansAnimalsMiceCell Line, TumorCell MovementMice, NudeGene Expression Regulation, Neoplastic

Stichwörter der Autor:innen

Cell cycleFAM111BPI3K/AKTPRIM2Pancreatic ductal adenocarcinoma

Autor:innen und Institutionen

  • University of Chinese Academy of Sciences (UCAS) Chongqing School, Chongqing Medical University, Chongqing, P. R. China.
  • Chongqing Institute of Green and Intelligent Technology, Chinese Academy of Sciences, Chongqing, 400174, P. R. China.
  • Chongqing School, University of Chinese Academy of Sciences (UCAS), Chongqing, P. R. China.
  • Institute of Hepatopancreatobiliary Surgery, Chongqing General Hospital, Chongqing University, Chongqing, P. R. China.
  • Chongqing Key Laboratory of Intelligent Medicine Engineering for Hepatopancreatobiliary Diseases, Chongqing, 401147, P. R. China.
  • Department of Pathophysiology, College of High Altitude Military Medicine, Third Military Medical University, Chongqing, 400038, P. R. China. nibing@tmmu.edu.cn.

Förderung

  • National Natural Science Foundation of China
  • Technology Innovation and Application Development Project of Chongqing, China

Zitieren

APA

Yin, J., Qin, F., Chen, H., Wang, X., Xia, R., Ni, B., & Wang, H. (2024). PRIM2 promotes proliferation and metastasis of pancreatic ductal adenocarcinoma through interactions with FAM111B. Medical Oncology. https://doi.org/10.1007/s12032-024-02554-8

Vancouver

Yin J, Qin F, Chen H, Wang X, Xia R, Ni B, et al. PRIM2 promotes proliferation and metastasis of pancreatic ductal adenocarcinoma through interactions with FAM111B. Medical Oncology. 2024. doi:10.1007/s12032-024-02554-8

BibTeX
@article{Yin2024,
  author = {Yin, Jingyang and Qin, Fanbo and Chen, Hui and Wang, Xianxing and Xia, Renpei and Ni, Bing and Wang, Huaizhi},
  title = {PRIM2 promotes proliferation and metastasis of pancreatic ductal adenocarcinoma through interactions with FAM111B},
  journal = {Medical Oncology},
  year = {2024},
  doi = {10.1007/s12032-024-02554-8}
}
Kostenlos starten →